Stock Comparison
NVDA vs RXRX
NVIDIA Corp vs Recursion Pharmaceuticals Inc
The Verdict
RXRX takes this one.
Head-to-Head
Market Cap
P/E Ratio
Profit Margin
Return on Equity
Debt-to-Equity
Overall Risk
DVR Score
The Deep Dive
NVIDIA continues to demonstrate unparalleled leadership in AI and accelerated computing, highlighted by its exceptional Q1 FY2027 results: $81.6 billion revenue (+85% YoY), $1.87 non-GAAP EPS (+140% YoY), and a robust $48.6 billion in free cash flow. The strategic vision for pervasive AI, robotics, and the Omniverse targets vast, expanding markets, underpinned by the critical CUDA platform and con...
Full NVDA AnalysisRecursion Pharmaceuticals (RXRX) continues to present a compelling long-term vision leveraging its AI/ML Biofoundry to disrupt drug discovery, backed by a strong cash position ($665.2M). The analyst targets (median $9.0) significantly above the current price ($3.44) indicate underlying institutional belief in its future. However, the Q1 2026 earnings revealed a significant challenge: collaboration...
Full RXRX AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Analyze Any Stock →Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.